These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 15603193)

  • 1. CoVal fusions: a therapeutic vaccine platform using heat shock proteins to treat chronic viral infection and cancer.
    Neefe JR; Chu NR; Mizzen L
    Dev Biol (Basel); 2004; 116():193-200; discussion 229-36. PubMed ID: 15603193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel therapeutic fusion protein vaccine by two different families of heat shock proteins linked with HPV16 E7 generates potent antitumor immunity and antiangiogenesis.
    Liu B; Ye D; Song X; Zhao X; Yi L; Song J; Zhang Z; Zhao Q
    Vaccine; 2008 Mar; 26(10):1387-96. PubMed ID: 18272260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic, therapeutic and anti-metastatic effects of an HPV-16mE6Delta/mE7/TBhsp70Delta fusion protein vaccine in an animal model.
    Qian X; Lu Y; Liu Q; Chen K; Zhao Q; Song J
    Immunol Lett; 2006 Feb; 102(2):191-201. PubMed ID: 16242781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A trial of SGN-00101 (HspE7) to treat high-grade anal intraepithelial neoplasia in HIV-positive individuals.
    Palefsky JM; Berry JM; Jay N; Krogstad M; Da Costa M; Darragh TM; Lee JY
    AIDS; 2006 May; 20(8):1151-5. PubMed ID: 16691066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in heat shock protein-based cancer vaccines.
    Wang HH; Mao CY; Teng LS; Cao J
    Hepatobiliary Pancreat Dis Int; 2006 Feb; 5(1):22-7. PubMed ID: 16481277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Technology evaluation: HspE7, StressGen Biotechnologies Corp.
    Hunt S
    Curr Opin Mol Ther; 2001 Aug; 3(4):413-7. PubMed ID: 11525566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heat shock protein-based cancer vaccines.
    Oki Y; Younes A
    Expert Rev Vaccines; 2004 Aug; 3(4):403-11. PubMed ID: 15270645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A broadly applicable, personalized heat shock protein-mediated oncolytic tumor vaccine.
    Huang XF; Ren W; Rollins L; Pittman P; Shah M; Shen L; Gu Q; Strube R; Hu F; Chen SY
    Cancer Res; 2003 Nov; 63(21):7321-9. PubMed ID: 14612530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting.
    Gray A; Raff AB; Chiriva-Internati M; Chen SY; Kast WM
    Immunol Rev; 2008 Apr; 222():316-27. PubMed ID: 18364011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccines against human papillomavirus and cervical cancer: promises and challenges.
    Mahdavi A; Monk BJ
    Oncologist; 2005 Aug; 10(7):528-38. PubMed ID: 16079320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heat-shock protein-based anticancer immunotherapy: an idea whose time has come.
    Ménoret A; Chandawarkar R
    Semin Oncol; 1998 Dec; 25(6):654-60. PubMed ID: 9865680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination.
    Vandepapeliere P; Barrasso R; Meijer CJ; Walboomers JM; Wettendorff M; Stanberry LR; Lacey CJ
    J Infect Dis; 2005 Dec; 192(12):2099-107. PubMed ID: 16288373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination strategies for the prevention of cervical cancer.
    Maclean J; Rybicki EP; Williamson AL
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):97-107. PubMed ID: 15757442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hsp-based tumor vaccines: state-of-the-art and future directions.
    Takakura Y; Takemoto S; Nishikawa M
    Curr Opin Mol Ther; 2007 Aug; 9(4):385-91. PubMed ID: 17694451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic cancer vaccines: using unique antigens.
    Lewis JJ
    Proc Natl Acad Sci U S A; 2004 Oct; 101 Suppl 2(Suppl 2):14653-6. PubMed ID: 15297620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human papillomavirus vaccines for the treatment of cervical cancer.
    Sin JI
    Expert Rev Vaccines; 2006 Dec; 5(6):783-92. PubMed ID: 17184217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human papillomavirus vaccines for the prevention and treatment of cervical cancer.
    Tomson TT; Roden RB; Wu TC
    Curr Opin Investig Drugs; 2004 Dec; 5(12):1247-61. PubMed ID: 15648945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.
    Santin AD; Bellone S; Palmieri M; Ravaggi A; Romani C; Tassi R; Roman JJ; Burnett A; Pecorelli S; Cannon MJ
    Gynecol Oncol; 2006 Mar; 100(3):469-78. PubMed ID: 16249018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.